newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the ",